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Abstract
1

AB toxins consist of an enzymatic A subunit and a cell-binding B subunit . These toxins are secreted into the extracellular milieu, but they act
upon targets within the eukaryotic cytosol. Some AB toxins travel by vesicle carriers from the cell surface to the endoplasmic reticulum (ER)
2-4
before entering the cytosol . In the ER, the catalytic A chain dissociates from the rest of the toxin and moves through a protein-conducting
5
channel to reach its cytosolic target . The translocated, cytosolic A chain is difficult to detect because toxin trafficking to the ER is an extremely
inefficient process: most internalized toxin is routed to the lysosomes for degradation, so only a small fraction of surface-bound toxin reaches the
6-12
Golgi apparatus and ER .
To monitor toxin translocation from the ER to the cytosol in cultured cells, we combined a subcellular fractionation protocol with the highly
13-15
sensitive detection method of surface plasmon resonance (SPR)
. The plasma membrane of toxin-treated cells is selectively permeabilized
with digitonin, allowing collection of a cytosolic fraction which is subsequently perfused over an SPR sensor coated with an anti-toxin A chain
antibody. The antibody-coated sensor can capture and detect pg/mL quantities of cytosolic toxin. With this protocol, it is possible to follow the
kinetics of toxin entry into the cytosol and to characterize inhibitory effects on the translocation event. The concentration of cytosolic toxin can
also be calculated from a standard curve generated with known quantities of A chain standards that have been perfused over the sensor. Our
method represents a rapid, sensitive, and quantitative detection system that does not require radiolabeling or other modifications to the target
toxin.

Video Link
The video component of this article can be found at http://www.jove.com/video/3686/

Protocol

1. Preparation of digitonin
1. Add 500 μL of 100% ethanol to a microcentrifuge tube and place it in a heat block set at 80 °C for 10 min.
2. Dissolve 2.5 mg of digitonin in 250 μL of the heated ethanol to produce a 1% stock solution of digitonin.
3. To generate a working solution of 0.04% digitonin, add 40 μL of the digitonin stock solution to 960 μL of HCN buffer (50 mM Hepes pH 7.5,
150 mM NaCl, 2 mM CaCl2, 10 mM N-ethylmaleimide, and a protease inhibitor cocktail).

2. Cell intoxication and permeabilization
Our translocation assay can be applied to a range of toxins and cell lines. Below, we provide a detailed protocol for the detection of cholera toxin
(CT). An overview of the procedure is provided in Figure 1.
1. HeLa cells are seeded in 6-well plates containing 1 mL DMEM supplemented with 10% fetal bovine serum and antibiotic-antimycotic to
6
achieve 1x10 cells/well after an overnight incubation at 37 °C. To generate enough cytosolic toxin for reproducible detection, triplicate wells
are required for each condition.
2. Following an overnight incubation, replace the culture medium with 1 mL DMEM containing 100 ng/mL of ganglioside GM1. This increases
the number of binding sites for CT, as the GM1 receptor of CT will intercalate into the plasma membrane of cells exposed to a solution of
GM1.
3. After a 1 hr incubation at 37 °C, remove the GM1-containing medium and wash the cells twice with DMEM. Then, place the cells at 4 °C for
30 min in 1 mL DMEM containing 1 μg/mL of CT.
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4. Remove the toxin-containing medium, wash the cells twice with DMEM, and incubate the cells in 1 mL DMEM at 37 °C for the desired time
interval(s).
5. At the end of each chase period, wash the cells with PBS and incubate each well with 250 μL of 0.5 mM EDTA in PBS. Let the cells sit for 10
min at room temperature and then remove them from the 6-well plate by vigorous trituration with a p1000 pipetman. After one well of cells has
been collected, combine it with the second and then third well from the same condition. Cell scrapers can also be used to collect the cells.
6. Place the combined cell suspension from the three replicate wells (750 μL total volume) in a single microcentrifuge tube, and spin it in a
tabletop microcentrifuge for 5 min at 5,000 x g. Cell pellets of roughly equivalent size should be obtained for all conditions.
7. Discard the supernatant and resuspend the cell pellet in 100 μL of the 0.04% working solution of digitonin. Place the cell suspension on ice
for 10 min.
8. Spin the digitonin-permeabilized cells at 16,000 x g for 10 min in a tabletop microcentrifuge. Transfer the cytosol-containing supernatant
fraction to a fresh microcentrifuge tube, and retain the organelle-containing pellet fraction.

3. Sample preparation
1. Cytosol-containing supernatant fractions are diluted in HCN buffer to a final volume of 1 mL. Sample volumes of at least 1 mL are necessary
to ensure air is purged from the 500 μL sample loop before injection.
2. Organelle-containing pellet fractions are resuspended in 1 mL of HCN buffer containing 1% Triton X-100. Addition of detergent is necessary
to release the membrane-encased pool of toxin.
3. Toxin standards at concentrations of 100, 10, 1, and 0.1 ng/mL are prepared in HCN buffer.
4. Parallel sets of cytosolic and organelle fractions are prepared for a control experiment to confirm the fidelity of the fractionation procedure.
Fractions generated as described in Section 2 are resuspended in 20 μL of 4x sample buffer (cytosolic fraction) or 120 μL of 1x sample buffer
(organelle fraction). Equivalent volumes of each fraction are resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis and
probed by Western blot analysis to demonstrate the partitioning of a cytosolic protein in the supernatant fraction and a soluble, resident ER
16-19
protein in the pellet fraction
.

4. SPR slide preparation
1. The Reichert SR7000 SPR Refractometer is used for SPR experiments.
2. Set a gold-plated glass slide with a self-assembled monolayer in the SPR instrument. To activate the sensor slide, perfuse a 1:1 (v:v) solution
of 0.4 M EDC and 0.1 M NHS over the slide for 10 min at a flow rate of 41 μL/min. All subsequent perfusions will use the same flow rate.
3. To remove the EDC:NHS activation buffer, wash the plate for 5 min with PBS containing 0.05% Tween 20 (PBST). The plate now contains
reactive amide tethers due to uncapping by the EDC:NHS solution.
4. Perfuse an anti-CTA antibody over the activated sensor slide at a dilution of 1:20,000 in 20 mM sodium acetate (pH 5.5) for 15 min. An initial
drop in the refractive index unit (RIU) will be seen due to the pH change. This will be followed by an increase in the RIU as the antibody is
captured by the amide-reactive tethers on the sensor slide.
5. Remove unbound antibody from the sensor slide with a 5 minute PBST wash. The RIU signal produced by the captured antibody will plateau
and stabilize, providing a new baseline signal.
6. Perfuse 1 M ethanolamine (pH 8.5) over the sensor slide for 5 min. This caps and inactivates any unbound tethers left on the sensor slide.

5. SPR analysis of samples
1. To establish a baseline reading, perfuse PBST over the antibody-coated sensor for 5 min.
2. Perfuse an experimental sample or toxin standard over the sensor for 300 sec. Remove the ligand from the buffer and perfuse PBST over the
sensor for another 200 sec.
3. Following each perfusion, bound toxin is removed from the sensor by a 100 sec wash with PBST at pH 5.0. This will return the signal to its
initial baseline reading, thus allowing another sample to be processed on the same sensor.
4. Before loading a new sample, push a small amount of air through the sample loop to expel any residual fluid from the prior sample. Using the
procedure outlined in 5.2-5.4, we have run up to 12 samples on one slide without substantial loss of the baseline signal.
5. Data analysis is performed with the Scrubber 2 software, and the Igor software is used for figure preparation.

6. Representative Results
3, 12

Pertussis toxin (PT) is an AB toxin that moves from the cell surface to the ER before its A chain (PTS1) enters the cytosol
. As shown in
Figure 2, our SPR-based translocation assay could detect PTS1 in the cytosol of intoxicated CHO cells. No signal was generated from the
cytosol of unintoxicated cells, which confirmed the anti-PTS1 antibody did not cross-react with a component of the host cytosol. The cytosolic
fraction from cells intoxicated in the presence of brefeldin A (BfA) also failed to produce a positive signal. BfA prevents toxin transport to the
6-8, 12, 20-25
ER translocation site
and, thus, A chain delivery to the cytosol. At the end of each run, bound toxin is stripped from the sensor slide.
This allowed multiple samples to be screened on a single sensor slide and thereby provided a direct comparison between results obtained with
different experimental conditions.
4

CT is another AB-type, ER-translocating toxin . In Figure 3A, CTA1 was detected in the cytosolic fraction from CT-treated HeLa cells. This
emphasized that our methodology works with multiple cell types and can be applied to any toxin for which an anti-A chain antibody is available.
No signal was detected when the cytosolic fraction from CT-treated cells was perfused over an SPR sensor coated with an anti-CTB antibody
(Fig. 3B), thus demonstrating that the CTA1 subunit but not the cell-binding CTB pentamer enters the cytosol. Figure 3C shows the signal from
the organelle fraction is off-scale in comparison to the weaker signal from the cytosolic fraction. This was consistent with the known inefficiency
6, 7
of CT transport to the ER translocation site , which in turn limits the amount of toxin that can reach the cytosol. Furthermore, the organelle
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fraction contains CT holotoxin as well as ER-localized CTA1, so the resulting SPR signal for the organelle fraction is inflated by the additional
mass of the holotoxin-associated CTB pentamer. Thus, it is not practical to plot data from the organelle and cytosolic fractions on the same
sensorgram.
Our assay can monitor the time-dependent accumulation of translocated, cytosolic toxin (Fig 4). Cells were exposed to CT at 4 °C, a temperature
that allows toxin binding to the plasma membrane but prevents internalization of the cell-associated toxin. After the removal of unbound toxin,
the cells were warmed to 37 °C. Both toxin transport to the ER and A chain translocation to the cytosol can occur at this temperature. No toxin
was detected in the cytosol 15 minutes after warming to 37 °C. This reflected the lag time required for (i) holotoxin trafficking to the ER; (ii) A/B
subunit dissociation in the ER; and (iii) A chain export to the cytosol. A minor pool of cytosolic toxin was detected after 30 minutes at 37 °C, and
progressively larger quantities of cytosolic toxin were detected after the 45 and 60 minute chase intervals. Even greater levels of cytosolic toxin
17
were detected after a 5 hour chase interval , thus demonstrating a continual, long-term delivery of cell-associated toxin to the host cytosol.
Our assay can also detect the inhibition of toxin translocation to the cytosol (Fig. 5). Cells treated with 10% dimethyl sulfoxide (DMSO), a
chemical chaperone that prevents the thermal disordering of the isolated CTA1 subunit (T. Banerjee and K. Teter, unpublished observations),
exhibited low levels of cytosolic CTA1 in comparison to the untreated control cells. Unfolding of the toxin A chain is a prerequisite for
16-18
translocation to the cytosol
, so the DMSO-induced stabilization of CTA1 accordingly prevented its movement from the ER to the cytosol.
14,

The association rate constant (ka) calculated from SPR experiments is directly proportional to the concentration of ligand in the perfusion buffer
15, 26

. Thus, it is possible to determine the concentration of cytosolic toxin from a graph that plots the ka values for toxin standards as a function
of toxin concentration. This procedure was used to quantify the DMSO-induced block of toxin translocation presented in Figure 5: the standard
curve generated from known concentrations of toxin was used to calculate a cytosolic CTA1 concentration of 0.3 ng/mL for untreated cells and
0.1 ng/mL for DMSO-treated cells (Fig. 6). The inhibition of CTA1 unfolding by DMSO thus generated a 3-fold reduction in the ER-to-cytosol
translocation of CTA1.
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Figure 1. Protocol overview. (A) Cells are incubated with the AB toxin at 4 °C, a temperature that allows toxin binding to the cell surface but
prevents toxin endocytosis. The A and B subunits of the toxin are represented by red and blue circles, respectively. (B) Unbound toxin is
removed from the medium, and cells are warmed to 37 °C in order to promote endocytosis and retrograde transport of the holotoxin to the
ER. Holotoxin dissociation occurs in the ER, which allows the isolated A chain to enter the cytosol by passing through a protein-conducting
channel(s) in the ER membrane. (C) Cells are treated with digitonin in order to selectively permeabilize the plasma membrane. (D) Centrifugation
is used to partition the cells into separate cytosolic and organelle fractions. The cytosol is squeezed out of the cell through the digitoningenerated pores and is located in the supernatant. The intact, membrane-bound organelles are found in the pellet fraction. (E) To detect the
translocated pool of toxin A chain in the host cytosol, the supernatant fraction is perfused over an SPR sensor coated with an anti-A chain
antibody.

Figure 2. Detection of PTS1 translocation into the host cytosol. CHO cells were pulse-labeled at 4 °C for 30 min with 1 μg/mL of PT. The cells
were then chased for 3 hr at 37 °C in toxin-free medium containing no additions (intoxicated) or 5 μg BfA/mL (+BfA intoxicated). Permeabilization
of the plasma membrane with digitonin was used to partition cell extracts into separate organelle and cytosolic fractions. An SPR sensor coated
with an anti-PTS1 antibody was used to detect the cytosolic pool of PTS1 from untreated or BfA-treated cells. PTS1 standards were perfused
over the sensor as positive controls, while the cytosolic fraction from unintoxicated cells was perfused over the sensor slide as a negative control.
At the end of each run, bound sample was stripped from the sensor slide.
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Figure 3. Detection of CTA1 translocation into the host cytosol. HeLa cells pulse-labeled at 4 °C with 1 μg/mL of CT were chased for 2 hr at 37
°C in toxin-free medium containing no additions (intoxicated) or 5 μg BfA/mL (+BfA intoxicated). Permeabilization of the plasma membrane with
digitonin was used to partition cell extracts into separate organelle and cytosolic fractions. (A) The cytosolic fractions were perfused over an SPR
sensor coated with an anti-CTA antibody. Known quantities of CTA were used as positive controls, while the cytosol from unintoxicated cells was
used as a negative control. (B) The cytosolic fraction from cells intoxicated in the absence of BfA was perfused over an SPR sensor coated with
an anti-CTB antibody. A purified CTB pentamer was perfused over the slide as a positive control. (C) The organelle fraction was solubilized with
Copyright © 2012 Journal of Visualized Experiments
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1% Triton X-100 before perfusion over a SPR sensor coated with an anti-CTA antibody. For comparative purposes, the cytosolic fraction (1 mL
final volume) from the same cell extract and a CTA standard were also perfused over the sensor. For all panels, bound sample was stripped from
the sensor at the end of each run.

Figure 4. Kinetics of CTA1 entry into the cytosol. HeLa cells pulse-labeled at 4 °C with 1 μg/mL of CT were chased for 15, 30, 45, or 60 min at
37 °C in toxin-free medium. To detect the translocated pool of toxin, cytosolic fractions from digitonin-permeabilized cells were perfused over an
SPR sensor coated with an anti-CTA antibody. CTA standards were perfused over the sensor as well. At the end of each run, bound sample was
stripped from the sensor slide.
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Figure 5. Inhibition of CTA1 translocation by DMSO. HeLa cells pulse-labeled at 4 °C with 1 μg/mL of CT were chased for 2 hr at 37 °C in
toxin-free medium containing no additions (intoxicated) or 10% DMSO (+DMSO intoxicated). To detect the translocated pool of toxin, cytosolic
fractions from digitonin-permeabilized cells were perfused over an SPR sensor coated with an anti-CTA antibody. CTA standards (100, 10, 1, and
0.1 ng/mL) were perfused over the sensor as positive controls; only the 1 and 0.1 ng/mL standards are shown for scaling purposes. The cytosol
from unintoxicated cells was used as a negative control. At the end of each run, bound sample was stripped from the sensor slide.
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Figure 6. Calculation of cytosolic CTA1. ka values for the CTA standards from Figure 5 were plotted as a function of toxin concentration. The
resulting standard curve was used to determine, based on the ka values of the experimental samples from Figure 5, the concentration of
cytosolic CTA1 in untreated and DMSO-treated cells. Toxin standards are presented as filled circles; the untreated cytosol is presented as an
open square; and the DMSO-treated cytosol is presented as an open circle. The averages ± ranges of two independent experiments are shown.
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Discussion

Comparison to existing methodology
Our SPR-based translocation assay represents a rapid, sensitive, and quantitative method to detect toxin delivery into the host cytosol. The
technique does not require radiolabeling or other modifications to the toxin, and it can be applied to any toxin for which an anti-toxin A chain
antibody is available. Existing methods to monitor toxin passage into the cytosol also rely upon a subcellular fractionation protocol to partition cell
11, 23, 27, 28
extracts into separate cytosol and membrane fractions
. These methods use Western blot or radiolabels to detect the cytosolic pool of
toxin. The former approach is semi-quantitative at best and suffers from relatively poor sensitivity. Even radiolabeling protocols can take weeks
to generate a result, owing to the low levels of toxin which reach the cytosol. While quantitative analysis with a radiolabeled toxin can determine
the relative percentage of cell-associated toxin which enters the cytosol, this approach cannot directly determine the exact number of cytosolic
toxin molecules. Comparing the sensitivity of SPR toxin detection to the detection of radiolabeled toxin is therefore problematic, as the quantity of
cytosolic toxin can be calculated by SPR but not by radiolabeling.
Other translocation assays bypass the upstream toxin trafficking steps and deliver the toxin A chain directly to the ER using either plasmid29-38
based expression systems or in vitro transcription / translation systems
. For either method, an amino-terminal signal sequence targets the A
chain for co-translational import into the ER lumen. Export of the synthesized A chain from the ER is then detected by subcellular fractionation,
differential centrifugation, toxin activity in the cytosol, proteasomal degradation of the translocated toxin, and/or a cytosolic-specific toxin
modification. Subsets of these approaches focus solely on the translocation event, can be used for in vitro reconstitution experiments, and
produce elevated levels of toxin for detection and co-immunoprecipitation studies. However, the methodologies cannot determine the kinetics or
efficiency of toxin delivery from the cell surface to the cytosol. It is also possible that the translocated A chain does not enter the ER in the same
conformational state as the holotoxin-delivered A chain. Other aspects of host-toxin interactions are missing from these procedures, such as the
A/B dissociation event. Thus, there are both strengths and weaknesses to monitoring translocation with A chains that are synthesized directly in
the ER.
Toxin translocation is often detected through intoxication assays. The cytotoxic or cytopathic effect generated by exogenously applied toxin
demonstrates the toxin A chain has reached its cytosolic target. Obviously, this is an indirect measure of translocation that monitors toxin activity
in the cytosol rather than the physical presence of cytosolic toxin. Thus, the technique can neither quantify the levels of cytosolic toxin nor
directly detect altered processing of the translocated toxin. There are also scenarios in which a direct correlation between cytosolic toxin levels
and toxin activity do not exist, such as the possible need for a threshold concentration of cytosolic toxin to elicit a cellular response or when toxin
activity produces a saturated cellular response. Still, intoxication assays can provide a functional correlation to assays which directly document
the translocation event. We have previously used this strategy to demonstrate an inhibition of A chain translocation corresponds to an inhibition
17-19
of cellular intoxication
.
In summary, there are multiple methods to detect toxin delivery to the cytosol. Our SPR-based approach has the advantages of providing rapid,
sensitive, and quantitative results. The data can also be supplemented with experiments using one of the aforementioned older strategies to
generate a stronger conclusion.

Future applications
Our label-free method for the detection and quantification of cytosolic toxin provides investigators with the flexibility to address many outstanding
questions regarding the cell biology of intoxication. For example, it is possible to establish the efficiency of A chain delivery to the cytosol by
calculating the percentage of surface-bound toxin that reaches the cytosol. It is also possible to quantify the total amount of cytosolic toxin
and, by extension, the number of cytosolic toxin molecules per cell. It is believed that one molecule of cytosolic diphtheria toxin is sufficient
39
to elicit a complete cytopathic/cytotoxic effect ; this model can now be tested with other toxins using our translocation assay and correlative
intoxication assays. Thus, our SPR-based assay should be able to determine how many molecules of cytosolic toxin are required for productive
intoxication. Our technique can also track the persistence of cytosolic toxin. Substantial degradation of the translocated A chain would limit and
possibly reduce its cytosolic concentration over time, which would imply the effects of intoxication could be reversed if A chain access to the
cytosol was restricted after the initial toxin exposure. Furthermore, the extracellular medium and membrane pellet from intoxicated cells can be
used to track the quantity of secreted toxin or toxin residing in the endomembrane system, respectively. Comparative studies of extracellular,
endomembrane-localized, and cytosolic toxin can be used to examine how the cell biology of intoxication varies for different ER-translocating
19
toxins. Our assay can also be used to dissect the toxin-specific cellular factors required for the translocation event . It should be possible to
adapt our methodology to track the endosome-to-cytosol translocation of other AB toxins such as anthrax lethal factor and diphtheria toxin.
Finally, viral entry into the host cytosol could possibly be monitored with a similar experimental procedure.

Limitations
Conditions that inhibit toxin trafficking to the ER will also prevent toxin delivery to the cytosol. This was demonstrated by the absence of cytosolic
toxin in BfA-treated cells (Figs. 2, 3A). Thus, additional control experiments are required when using this method to examine potential blocks
6, 40-43
of toxin translocation. For some AB toxins, reduction of a disulfide bond that tethers the catalytic subunit to its holotoxin occurs in the ER
.
16, 18
The redox status of the A chain can accordingly be used as a measure of toxin transport to the ER
. Recombinant toxins containing the
12,
consensus sequence for N-linked glycosylation, a modification that is initiated in the ER, have also been used to detect toxin entry into the ER
23, 44-46
. Finally, as discussed above, alternative protocols involving co-translational insertion of the toxin A chain into the ER lumen can verify an
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inhibitory effect on the translocation event. For example, our SPR-based translocation assay demonstrated a functional role for Hsp90 in CTA1
19
translocation that was confirmed with a plasmid-based system that expressed CTA1 directly in the ER lumen .
The A chains of ER-translocating toxins exhibit a strong arginine-over-lysine amino acid bias that allows the translocated toxin to evade ubiquitin47-50
dependent proteasomal degradation
. However, degradation of the cytosolic toxin still occurs by a relatively slow, ubiquitin-independent
51, 52
proteasomal mechanism
. Conditions that enhance proteasomal activity could thus skew the results of our translocation assay by reducing
the pool of translocated toxin in the cytosolic fraction. Cells exposed to a proteasome inhibitor can be used to control for this possibility; an
increase in cytosolic toxin resulting from proteasomal inhibition would indicate the toxin could indeed reach the cytosol but was degraded before
detection.
It should be noted that these considerations apply to subsets of the aforementioned alternative approaches and are not unique to our method. As
mentioned earlier, the best strategy for characterizing the translocation event is to use a combination of well-controlled techniques.

Critical steps and trouble-shooting
Chemical preparation is a critical step for the assay. Digitonin does not dissolve easily, and it should be prepared fresh for every experiment.
Likewise, fresh PBST should be used for SPR analysis. The EDC:NHS activation buffer should be prepared immediately before use; it will not
retain activity if stored after mixing the two solutions. However, separate aliquots of EDC and NHS can be stored at -80°C and thawed once
before use. All solutions, including the samples, should be de-gassed before injection. This will prevent air-induced spikes in the SPR signal.
The cell type to be used for this assay must express enough toxin receptors to allow a detectable pool of toxin A chain to reach the cytosol. In
some cases, such as the pre-treatment of HeLa cells with GM1 before CT challenge, additional toxin receptors can be added to the surface of
target cells. The cell type must also be susceptible to selective permeabilization of the plasma membrane with digitonin. The protocol described
herein is effective with HeLa and CHO cells, but other cell types will require an optimization step using Western blot analysis to monitor the
clean separation of organelle and cytosolic fractions. We routinely follow the distributions of protein disulfide isomerase (a soluble ER protein)
16-19
16-19
and Hsp90 (a cytosolic protein) for this purpose
. The exclusive partitioning of protein disulfide isomerase into the pellet fraction
also
ensures that the organelles collected in the membrane pellet are intact. This is a crucial aspect of our method, as the unintentional rupture
of intracellular organelles would introduce error into the system by releasing endomembrane-restricted toxin into the cytosolic fraction. SPRbased experiments can also be used to demonstrate that the cytosolic pool of toxin results from a translocation event rather than from the lysis
of intracellular organelles. For example, no toxin was detected in the cytosol of BfA-treated cells (Figs. 2, 3A) or cells exposed to toxin for only
15 minutes (Fig. 4). Likewise, the B subunit of CT was not detected in the cytosolic fraction after a two hour toxin exposure (Fig. 3B). Had our
protocol resulted in the permeabilization of internal membranes, we would have detected a cytosolic pool of toxin for each of the aforementioned
conditions. Establishing the proper protocol for reproducible, selective permeabilization of the plasma membrane is likely to represent the ratelimiting step for assay implementation. Other options for plasma membrane permeabilization are available, but we found that digitonin treatment
provided more consistent results than other methods such as treatment with streptolysin O.
The quality of the antibody will also determine the sensitivity of the assay, which can be established with serial dilutions of a toxin standard.
For example, we can reproducibly detect as little as 0.1 ng/mL of either PTS1 or CTA standard (Figs. 2-6). The anti-A chain antibody should
not recognize the toxin B subunit, and unintoxicated cells should always be used as a control to ensure the antibody does not cross-react with
proteins in the host cell. Preliminary experiments will need to optimize the conditions for stripping bound toxin from the antibody, as this can differ
for different anti-toxin antibodies.
When monitoring toxin translocation under altered cellular conditions, the toxin standards and cytosolic fraction from untreated control cells
should be supplemented to match the conditions in the experimental sample. For example, CTA standards and the untreated cytosolic fraction
from Figure 5 were supplemented with 1% DMSO to match the final drug concentration in the cytosolic fraction from DMSO-treated cells. This
eliminates possible differences in the SPR signals that might arise from differences in the chemical composition of the collected fractions.
Comparisons between cytosolic and organelle fractions would likewise require the addition of 1% Triton X-100 to the cytosolic fraction and
standards, as this detergent is used to release the membrane-encased toxin from the organelle fraction for SPR detection. Preliminary
experiments have shown the presence of cytosol does not alter the SPR response to toxin standards, so it is not necessary to supplement the
toxin standards with cytosol from unintoxicated cells.
Antibody binding to the sensor slide will not occur if the EDC:NHS activation solution is old or if the slide is inserted into the instrument with the
gold side face down. Given the manufacturing process, there will be some plate-to-plate variability which can prevent proper EDC:NHS activation
and, thus, antibody capture. If antibody binding to the slide is poor, as indicated by a weakly elevated RIU, a second injection can deposit more
of the antibody on the plate. The RIU is an arbitrary unit that varies from one experiment to another depending on how much anti-toxin antibody
is deposited on the sensor. However, the on and off rates will remain constant.
It is preferable to use a Refractometer with dual channel perfusion chambers, as one channel can be used for the experimental sample and the
other channel can be used for buffer alone in order to correct for possible baseline drift. When using a dual chamber instrument, ensure that the
anti-toxin antibody is only added to one of the two channels. Samples will subsequently be run through both channels. With a single channel
instrument, the compensation for baseline drift involves collection of buffer alone data from the antibody-coated slide prior to sample injection.
Before the beginning of an SPR experiment, ensure the sensor slide is set tight in the instrument and all fittings are secure. Leaks resulting
from these issues will generate air spikes in the collected data. Leaks can also be detected by the absence of waste flow, which should always
be present. A sample volume greater than the volume of the injection loop is necessary to avoid air spikes as well - for example, we use 1 mL
sample volumes with a 500 μL injection loop. An inappropriate amount of immersion oil on the prism will prevent stabilization of the baseline
signal. Other issues relating to operation of the SPR instrument are addressed in the Users Guide and Technical Bulletins provided by Reichert.
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